Lung cancer screening method

Abstract

The present invention addresses the problem of providing a method for screening for lung cancer. Provided is a method for screening for lung cancer that includes (1) a step for detecting the SLC2A1 protein in a body fluid sample collected from a subject or in extracellular vesicles in the body fluid sample.

Claims

1. (1) A method for testing for lung cancer, comprising the step of detecting the SLC2A1 protein in an extracellular vesicle in a body fluid sample taken from a subject or in the extracellular vesicle in the body fluid sample.

2. The method according to claim 1, wherein the target for detection is the SLC2A1 protein in the extracellular vesicle.

3. The method according to claim 1, wherein step (1) comprises: (1a) a step of bringing an SLC2A1 protein-binding molecule into contact with the body fluid sample or the extracellular vesicle; and (1b) a step of measuring the amount or concentration of the SLC2A1 protein bound to the SLC2A1 protein-binding molecule.

4. The method according to claim 3, wherein in step (1a), the SLC2A1 protein-binding molecule, the extracellular vesicle-binding molecule, and the body fluid sample are brought into contact.

5. The method according to claim 1, wherein the body fluid sample is at least one selected from the group consisting of blood, serum, and plasma.

6. The method according to claim 1, wherein the subject is a human.

7. The method according to claim 1, wherein the subject is a human having pulmonary nodules.

8. The method according to claim 1, wherein the lung cancer is an early-stage lung cancer.

9. The method according to any one of claims 1 to 8, further comprising (2) determining whether or not the subject has lung cancer based on the amount or concentration of the SLC2A1 protein detected in step (1).

10. The method according to claim 9, wherein step (2) includes (2a) determining that the subject has lung cancer if the amount or concentration of the SLC2A1 protein detected in step (1) is equal to or greater than a cutoff value, and / or (2b) determining that the subject does not have lung cancer if the amount or concentration of the SLC2A1 protein detected in step (1) is equal to or less than a cutoff value.

11. A lung cancer diagnostic agent containing an SLC2A1 protein-binding molecule.

12. The diagnostic agent according to claim 11, further comprising an extracellular vesicle-binding molecule.

Images